Cargando…
Profiling the immune landscape in mucinous ovarian carcinoma
OBJECTIVE. Mucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer, with low response rates to standard chemotherapy, and very poor survival for patients diagnosed at advanced stage. There is a limited understanding of the MOC immune landscape, and consequently whether immune checkpoi...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374276/ https://www.ncbi.nlm.nih.gov/pubmed/36368129 http://dx.doi.org/10.1016/j.ygyno.2022.10.022 |
_version_ | 1785078739133005824 |
---|---|
author | Meagher, Nicola S. Hamilton, Phineas Milne, Katy Thornton, Shelby Harris, Bronwyn Weir, Ashley Alsop, Jennifer Bisinoto, Christiani Brenton, James D. Brooks-Wilson, Angela Chiu, Derek S. Cushing-Haugen, Kara L. Fereday, Sian Garsed, Dale W. Gayther, Simon A. Gentry-Maharaj, Aleksandra Gilks, Blake Jimenez-Linan, Mercedes Kennedy, Catherine J. Le, Nhu D. Piskorz, Anna M. Riggan, Marjorie J. Shah, Mitul Singh, Naveena Talhouk, Aline Widschwendter, Martin Bowtell, David D.L. Candido dos Reis, Francisco J. Cook, Linda S. Fortner, Renée T. García, María J. Harris, Holly R. Huntsman, David G. Karnezis, Anthony N. Köbel, Martin Menon, Usha Pharoah, Paul D.P. Doherty, Jennifer A. Anglesio, Michael S. Pike, Malcolm C. Pearce, Celeste Leigh Friedlander, Michael L. DeFazio, Anna Nelson, Brad H. Ramus, Susan J. |
author_facet | Meagher, Nicola S. Hamilton, Phineas Milne, Katy Thornton, Shelby Harris, Bronwyn Weir, Ashley Alsop, Jennifer Bisinoto, Christiani Brenton, James D. Brooks-Wilson, Angela Chiu, Derek S. Cushing-Haugen, Kara L. Fereday, Sian Garsed, Dale W. Gayther, Simon A. Gentry-Maharaj, Aleksandra Gilks, Blake Jimenez-Linan, Mercedes Kennedy, Catherine J. Le, Nhu D. Piskorz, Anna M. Riggan, Marjorie J. Shah, Mitul Singh, Naveena Talhouk, Aline Widschwendter, Martin Bowtell, David D.L. Candido dos Reis, Francisco J. Cook, Linda S. Fortner, Renée T. García, María J. Harris, Holly R. Huntsman, David G. Karnezis, Anthony N. Köbel, Martin Menon, Usha Pharoah, Paul D.P. Doherty, Jennifer A. Anglesio, Michael S. Pike, Malcolm C. Pearce, Celeste Leigh Friedlander, Michael L. DeFazio, Anna Nelson, Brad H. Ramus, Susan J. |
author_sort | Meagher, Nicola S. |
collection | PubMed |
description | OBJECTIVE. Mucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer, with low response rates to standard chemotherapy, and very poor survival for patients diagnosed at advanced stage. There is a limited understanding of the MOC immune landscape, and consequently whether immune checkpoint inhibitors could be considered for a subset of patients. METHODS. We performed multicolor immunohistochemistry (IHC) and immunofluorescence (IF) on tissue microarrays in a cohort of 126 MOC patients. Cell densities were calculated in the epithelial and stromal components for tumor-associated macrophages (CD68+/PD-L1+, CD68+/PD-L1−), T cells (CD3+/CD8−, CD3+/CD8+), putative T-regulatory cells (Tregs, FOXP3+), B cells (CD20+/CD79A+), plasma cells (CD20−/CD79a+), and PD-L1+ and PD-1+ cells, and compared these values with clinical factors. Univariate and multivariable Cox Proportional Hazards assessed overall survival. Unsupervised k-means clustering identified patient subsets with common patterns of immune cell infiltration. RESULTS. Mean densities of PD1+ cells, PD-L1− macrophages, CD4+ and CD8+ T cells, and FOXP3+ Tregs were higher in the stroma compared to the epithelium. Tumors from advanced (Stage III/IV) MOC had greater epithelial infiltration of PD-L1− macrophages, and fewer PD-L1+ macrophages compared with Stage I/II cancers (p = 0.004 and p = 0.014 respectively). Patients with high epithelial density of FOXP3+ cells, CD8+/FOXP3+ cells, or PD-L1− macrophages, had poorer survival, and high epithelial CD79a + plasma cells conferred better survival, all upon univariate analysis only. Clustering showed that most MOC (86%) had an immune depleted (cold) phenotype, with only a small proportion (11/76,14%) considered immune inflamed (hot) based on T cell and PD-L1 infiltrates. CONCLUSION. In summary, MOCs are mostly immunogenically ‘cold’, suggesting they may have limited response to current immunotherapies. |
format | Online Article Text |
id | pubmed-10374276 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
record_format | MEDLINE/PubMed |
spelling | pubmed-103742762023-07-27 Profiling the immune landscape in mucinous ovarian carcinoma Meagher, Nicola S. Hamilton, Phineas Milne, Katy Thornton, Shelby Harris, Bronwyn Weir, Ashley Alsop, Jennifer Bisinoto, Christiani Brenton, James D. Brooks-Wilson, Angela Chiu, Derek S. Cushing-Haugen, Kara L. Fereday, Sian Garsed, Dale W. Gayther, Simon A. Gentry-Maharaj, Aleksandra Gilks, Blake Jimenez-Linan, Mercedes Kennedy, Catherine J. Le, Nhu D. Piskorz, Anna M. Riggan, Marjorie J. Shah, Mitul Singh, Naveena Talhouk, Aline Widschwendter, Martin Bowtell, David D.L. Candido dos Reis, Francisco J. Cook, Linda S. Fortner, Renée T. García, María J. Harris, Holly R. Huntsman, David G. Karnezis, Anthony N. Köbel, Martin Menon, Usha Pharoah, Paul D.P. Doherty, Jennifer A. Anglesio, Michael S. Pike, Malcolm C. Pearce, Celeste Leigh Friedlander, Michael L. DeFazio, Anna Nelson, Brad H. Ramus, Susan J. Gynecol Oncol Article OBJECTIVE. Mucinous ovarian carcinoma (MOC) is a rare histotype of ovarian cancer, with low response rates to standard chemotherapy, and very poor survival for patients diagnosed at advanced stage. There is a limited understanding of the MOC immune landscape, and consequently whether immune checkpoint inhibitors could be considered for a subset of patients. METHODS. We performed multicolor immunohistochemistry (IHC) and immunofluorescence (IF) on tissue microarrays in a cohort of 126 MOC patients. Cell densities were calculated in the epithelial and stromal components for tumor-associated macrophages (CD68+/PD-L1+, CD68+/PD-L1−), T cells (CD3+/CD8−, CD3+/CD8+), putative T-regulatory cells (Tregs, FOXP3+), B cells (CD20+/CD79A+), plasma cells (CD20−/CD79a+), and PD-L1+ and PD-1+ cells, and compared these values with clinical factors. Univariate and multivariable Cox Proportional Hazards assessed overall survival. Unsupervised k-means clustering identified patient subsets with common patterns of immune cell infiltration. RESULTS. Mean densities of PD1+ cells, PD-L1− macrophages, CD4+ and CD8+ T cells, and FOXP3+ Tregs were higher in the stroma compared to the epithelium. Tumors from advanced (Stage III/IV) MOC had greater epithelial infiltration of PD-L1− macrophages, and fewer PD-L1+ macrophages compared with Stage I/II cancers (p = 0.004 and p = 0.014 respectively). Patients with high epithelial density of FOXP3+ cells, CD8+/FOXP3+ cells, or PD-L1− macrophages, had poorer survival, and high epithelial CD79a + plasma cells conferred better survival, all upon univariate analysis only. Clustering showed that most MOC (86%) had an immune depleted (cold) phenotype, with only a small proportion (11/76,14%) considered immune inflamed (hot) based on T cell and PD-L1 infiltrates. CONCLUSION. In summary, MOCs are mostly immunogenically ‘cold’, suggesting they may have limited response to current immunotherapies. 2023-01 2022-11-08 /pmc/articles/PMC10374276/ /pubmed/36368129 http://dx.doi.org/10.1016/j.ygyno.2022.10.022 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Meagher, Nicola S. Hamilton, Phineas Milne, Katy Thornton, Shelby Harris, Bronwyn Weir, Ashley Alsop, Jennifer Bisinoto, Christiani Brenton, James D. Brooks-Wilson, Angela Chiu, Derek S. Cushing-Haugen, Kara L. Fereday, Sian Garsed, Dale W. Gayther, Simon A. Gentry-Maharaj, Aleksandra Gilks, Blake Jimenez-Linan, Mercedes Kennedy, Catherine J. Le, Nhu D. Piskorz, Anna M. Riggan, Marjorie J. Shah, Mitul Singh, Naveena Talhouk, Aline Widschwendter, Martin Bowtell, David D.L. Candido dos Reis, Francisco J. Cook, Linda S. Fortner, Renée T. García, María J. Harris, Holly R. Huntsman, David G. Karnezis, Anthony N. Köbel, Martin Menon, Usha Pharoah, Paul D.P. Doherty, Jennifer A. Anglesio, Michael S. Pike, Malcolm C. Pearce, Celeste Leigh Friedlander, Michael L. DeFazio, Anna Nelson, Brad H. Ramus, Susan J. Profiling the immune landscape in mucinous ovarian carcinoma |
title | Profiling the immune landscape in mucinous ovarian carcinoma |
title_full | Profiling the immune landscape in mucinous ovarian carcinoma |
title_fullStr | Profiling the immune landscape in mucinous ovarian carcinoma |
title_full_unstemmed | Profiling the immune landscape in mucinous ovarian carcinoma |
title_short | Profiling the immune landscape in mucinous ovarian carcinoma |
title_sort | profiling the immune landscape in mucinous ovarian carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10374276/ https://www.ncbi.nlm.nih.gov/pubmed/36368129 http://dx.doi.org/10.1016/j.ygyno.2022.10.022 |
work_keys_str_mv | AT meaghernicolas profilingtheimmunelandscapeinmucinousovariancarcinoma AT hamiltonphineas profilingtheimmunelandscapeinmucinousovariancarcinoma AT milnekaty profilingtheimmunelandscapeinmucinousovariancarcinoma AT thorntonshelby profilingtheimmunelandscapeinmucinousovariancarcinoma AT harrisbronwyn profilingtheimmunelandscapeinmucinousovariancarcinoma AT weirashley profilingtheimmunelandscapeinmucinousovariancarcinoma AT alsopjennifer profilingtheimmunelandscapeinmucinousovariancarcinoma AT bisinotochristiani profilingtheimmunelandscapeinmucinousovariancarcinoma AT brentonjamesd profilingtheimmunelandscapeinmucinousovariancarcinoma AT brookswilsonangela profilingtheimmunelandscapeinmucinousovariancarcinoma AT chiudereks profilingtheimmunelandscapeinmucinousovariancarcinoma AT cushinghaugenkaral profilingtheimmunelandscapeinmucinousovariancarcinoma AT feredaysian profilingtheimmunelandscapeinmucinousovariancarcinoma AT garseddalew profilingtheimmunelandscapeinmucinousovariancarcinoma AT gaythersimona profilingtheimmunelandscapeinmucinousovariancarcinoma AT gentrymaharajaleksandra profilingtheimmunelandscapeinmucinousovariancarcinoma AT gilksblake profilingtheimmunelandscapeinmucinousovariancarcinoma AT jimenezlinanmercedes profilingtheimmunelandscapeinmucinousovariancarcinoma AT kennedycatherinej profilingtheimmunelandscapeinmucinousovariancarcinoma AT lenhud profilingtheimmunelandscapeinmucinousovariancarcinoma AT piskorzannam profilingtheimmunelandscapeinmucinousovariancarcinoma AT rigganmarjoriej profilingtheimmunelandscapeinmucinousovariancarcinoma AT shahmitul profilingtheimmunelandscapeinmucinousovariancarcinoma AT singhnaveena profilingtheimmunelandscapeinmucinousovariancarcinoma AT talhoukaline profilingtheimmunelandscapeinmucinousovariancarcinoma AT widschwendtermartin profilingtheimmunelandscapeinmucinousovariancarcinoma AT bowtelldaviddl profilingtheimmunelandscapeinmucinousovariancarcinoma AT candidodosreisfranciscoj profilingtheimmunelandscapeinmucinousovariancarcinoma AT cooklindas profilingtheimmunelandscapeinmucinousovariancarcinoma AT fortnerreneet profilingtheimmunelandscapeinmucinousovariancarcinoma AT garciamariaj profilingtheimmunelandscapeinmucinousovariancarcinoma AT harrishollyr profilingtheimmunelandscapeinmucinousovariancarcinoma AT huntsmandavidg profilingtheimmunelandscapeinmucinousovariancarcinoma AT karnezisanthonyn profilingtheimmunelandscapeinmucinousovariancarcinoma AT kobelmartin profilingtheimmunelandscapeinmucinousovariancarcinoma AT menonusha profilingtheimmunelandscapeinmucinousovariancarcinoma AT pharoahpauldp profilingtheimmunelandscapeinmucinousovariancarcinoma AT dohertyjennifera profilingtheimmunelandscapeinmucinousovariancarcinoma AT anglesiomichaels profilingtheimmunelandscapeinmucinousovariancarcinoma AT pikemalcolmc profilingtheimmunelandscapeinmucinousovariancarcinoma AT pearcecelesteleigh profilingtheimmunelandscapeinmucinousovariancarcinoma AT friedlandermichaell profilingtheimmunelandscapeinmucinousovariancarcinoma AT defazioanna profilingtheimmunelandscapeinmucinousovariancarcinoma AT nelsonbradh profilingtheimmunelandscapeinmucinousovariancarcinoma AT ramussusanj profilingtheimmunelandscapeinmucinousovariancarcinoma |